Currently, there is no cure for Parkinson’s Disease, however, certain medications can help improve symtoms.
Real-time quantification of brain activity during the psychedelic experience has been a major barrier within psychedelic research.
Sports luminaries including Mike Tyson will be among the world-leading speakers headlining the largest psychedelic medicine business conference next month.
Seattle council has unanimously voted to pass a resolution to decriminalise entheogenic substances.
Levitee Labs has announced it has listed on the Frankfurt Stock Exchange (FSE).
A free, virtual event is to explore the use of psychedelics for alcohol use disorder and binge drinking.
Results from a recent study have demonstrated a significant reduction in depressive symptoms and suicidality using ketamine as a solo treatment.
Data from Lobe Sciences has demonstrated that combination therapy of psilocybin and N-Acetylcysteine is more effective than monotherapy for mTBI and PTSD.
Better Life Pharma has obtained its first set of data on its lead compound TD-0148A, a second-generation LSD derivative, with further preclinical studies underway to determine...
Delix Therapeutics has raised $70m in a Series A funding round which is expected to fund its drug discovery platform of novel neuroplasticity-promoting compounds known as...
A first-of-its-kind study will investigate the use of MDMA-assisted psychotherapy for the treatment of female Hypoactive Sexual Desire Disorder (HSDD).
Heroic Hearts UK research director Grace Blest-Hopley discusses the organisation’s groundbreaking study that will investigate the use of psilocybin for treating brain trauma in veterans.
